Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Potentiator potential

Why Pfizer Venture Investments led Effector's $38.6M series C

Virginia Li, Staff Writer
July 29, 2017 2:48 AM UTC

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor.

On July 24, Effector closed a $19.3 million first tranche of a $38.6 million series C round led by new investor Pfizer Venture Investments. The second and final tranche is slated to close in 2018. The trigger is undisclosed...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Effector Therapeutics Inc.